TGM2 and celiac disease: In this context, the peptidomimetic inhibitor ZED1227, which is equipped with an α,β-unsaturated methyl ester as Michael acceptor for the active site cysteine residue of TGase 2 (Büchold et al. 2022), is in clinical evaluation for the treatment of celiac disease.